Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with pre‐existing primary immune thrombocytopenia (ITP) in Spain
María Eva Mingot‐Castellano, Patricia Alcalde‐Mellado, Cristina Pascual, Gloria Pérez Rus, Aida Calo Pérez, Maria Paz Martínez, Francisco José López‐Jaime, Lorena Abalo Perez, José Ramón González‐Porras, Fernanda López Fernández, Isabel S. Caparrós Miranda, Tomás José González‐López, María Esperanza Moreno Beltrán, Rebeca Rubio Escuin, Reyes Jiménez‐Bárcenas, on behalf GEPTI (Grupo Español de Trombocitopenia Inmune)
Abstract
Infections are one of the well-known precipitating factors for relapses in patients with immune thrombocytopenia (ITP). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can sometimes lead to or be associated with thrombocytopenia due to an increase in peripheral platelet destruction from inflammatory hyperactivation. Currently, we do not know if SARS-CoV-2 infection modifies the natural evolution of chronic or persistent ITP or if previous immunosuppression of patients with ITP influences the incidence and severity of coronavirus disease 2019 (COVID-19) in this group. The present study was an observational, multicentre, national series of 32 adult patients with pre-existing ITP and subsequent SARS-CoV-2 infection, collected by the Spanish ITP Group [Grupo Español de Trombocitopenia Inmune (GEPTI)].